MetaVia (MTVA) Investor presentation summary

Market opportunity and industry landscape

• Obesity and MASH represent rapidly expanding global markets, with obesity projected to reach $80B–$130B and MASH $20B–$35B annually by 2030, driven by increasing prevalence and new treatment options.

• Combination therapies are expected to become standard in MASH, increasing patient lifetime value.

• Major pharmaceutical companies have committed over $15 billion in obesity/MASH licensing deals in the past year, validating the sector's growth and potential.

Pipeline and clinical progress

• DA-1726, a novel GLP1R/GCGR dual agonist, demonstrated -9.1% weight loss, -3.8 inch waist reduction, -0.22 HbA1c, and -23.7% liver stiffness reduction at 48 mg in Phase 1, with mostly mild to moderate side effects.

• DA-1726 is advancing to dose optimization with stepwise titration up to 64 mg; data readout expected by year-end 2026.

• Vanoglipel (DA-1241), an oral GPR119 agonist, met primary endpoints in Phase 2a for presumed MASH, showing liver benefit and significant HbA1c reduction.

• Vanoglipel demonstrated additive benefits in combination therapy in preclinical models and is being positioned for partnerships.

Competitive positioning and safety

• DA-1726 shows potentially best-in-class efficacy for weight loss and glucose control compared to other dual agonists in early clinical data.

• Adverse events for DA-1726 were primarily mild or moderate, with no discontinuations in Phase 1; competitive agents showed higher rates of nausea, vomiting, and discontinuations.

• Vanoglipel was well-tolerated in clinical trials, with no treatment-related discontinuations and a favorable safety profile, including in combination therapy.